Print Page  Close Window

News Release

MyoKardia Announces Presentations at American Heart Association Scientific Sessions 2015

First Data Presentation from MyoKardia-Sponsored SHaRe Patient Registry

Company Co-Founder to Deliver Prestigious Distinguished Scientist Lecture

SOUTH SAN FRANCISCO, Calif., Nov. 4, 2015 (GLOBE NEWSWIRE) -- MyoKardia, Inc., a clinical stage biopharmaceutical company pioneering a precision medicine approach for the treatment of heritable cardiovascular diseases, today announced presentations at the American Heart Association (AHA) Scientific Sessions 2015, being held November 7-11 in Orlando, Fla.

Data on SHaRe Patient Registry to be Featured in Clinical Science Special Report Session

Carolyn Y. Ho, M.D., associate professor at Harvard Medical School and medical director of the Cardiovascular Genetics Center at Brigham and Women's Hospital, will present the first-ever findings from the Sarcomeric Human Cardiomyopathy Registry (SHaRe), a multicenter, international repository of clinical data on individuals with genetic heart disease, during a Clinical Science Special Report session.

In 2014, MyoKardia helped form SHaRe, a first-of-its-kind patient registry that aims to advance the understanding of hypertrophic cardiomyopathy (HCM) and dilated cardiomyopathy (DCM). Dr. Ho's presentation, titled "Examining Prevailing Genotype-Phenotype Correlations in Hypertrophic Cardiomyopathy: Findings From the Sarcomeric Human Cardiomyopathy Registry (SHaRe)," will be held during the "Novel Findings from Next Generation Registries" session on Monday, November 9 at 9:00 a.m. in the Chapin Theater.

MyoKardia Co-Founder to Deliver Distinguished Scientist Lecture

MyoKardia co-founder Christine (Kricket) Seidman, M.D., Howard Hughes Medical Institute investigator, professor of genetics and the Thomas W. Smith Professor of Medicine at Harvard Medical School and director of the Cardiovascular Genetics Center at Brigham and Women's Hospital, will deliver the Distinguished Scientist Lecture titled "Genetics of Heart Disease: From Mutation to Mechanism" on Tuesday, November 10 at 12:30 p.m. in the Chapin Theater.

Dr. Seidman received the AHA's Distinguished Scientist Award in 2003, which honors a prominent group of scientists and clinicians whose work has importantly advanced the understanding of cardiovascular diseases and stroke. This award was created to recognize AHA and American Stroke Association members for significant, original and sustained scientific contributions that have advanced the association's mission of "building healthier lives, free of cardiovascular diseases and stroke."

MyoKardia Co-Founders and Investigators to Present New Cardiomyopathy Research

Numerous MyoKardia co-founders and SHaRe registry investigators have been selected to present research or lectures on heritable cardiomyopathies and/or other topics in cardiovascular medicine at the AHA Scientific Sessions 2015. MyoKardia intends to leverage the new research and insights from these experts to better tailor its programs in HCM and DCM, and advance the company's goal of enabling precision medicines for patients with genetic heart disease. Such presenters associated with MyoKardia and SHaRe include:

  • MyoKardia co-founder Leslie Leinwand, Ph.D., BioFrontiers Institute at the University of Colorado, Boulder
  • MyoKardia co-founder Christine (Kricket) Seidman, M.D., Howard Hughes Medical Institute, Harvard Medical School and Brigham and Women's Hospital
  • MyoKardia co-founder Jonathan Seidman, Ph.D., Harvard Medical School
  • SHaRe investigator Euan Ashley, D.Phil., Stanford Center for Inherited Cardiovascular Disease
  • SHaRe investigator Steven Colan, M.D., Boston Children's Hospital and Harvard Medical School
  • SHaRe investigator Sharlene Day, M.D., University of Michigan
  • SHaRe investigator Carolyn Ho, M.D., Harvard Medical Center, Brigham and Women's Hospital
  • SHaRe investigator Iacopo Olivotto, M.D., Careggi University Hospital
  • SHaRe investigator Alexandre Pereira, Ph.D., University of Sao Paulo Medical School and Laboratory of Genetics & Molecular Cardiology at the Heart Institute

"MyoKardia is proud of our collaborators and their significant contributions. MyoKardia's continued support of this research helps bring us closer to our shared goal of making a difference for patients afflicted by heritable cardiomyopathies," said Tassos Gianakakos, President and Chief Executive Officer of MyoKardia. "We have supported SHaRe since its creation and believe this is the first of many important insights the registry will provide. Alongside the AHA, we recognize and celebrate Kricket's continued achievements, representing decades of tireless effort and dedication to patients."

About MyoKardia

MyoKardia (Nasdaq:MYOK) is a clinical stage biopharmaceutical company pioneering a precision medicine approach to discover, develop and commercialize targeted therapies for the treatment of serious and neglected rare cardiovascular diseases. MyoKardia's initial focus is on the treatment of heritable cardiomyopathies, a group of rare, genetically-driven forms of heart failure that result from biomechanical defects in cardiac muscle contraction. MyoKardia has used its precision medicine platform to generate a pipeline of therapeutic programs for the chronic treatment of the two most prevalent forms of heritable cardiomyopathy—hypertrophic cardiomyopathy, or HCM, and dilated cardiomyopathy, or DCM. MyoKardia's most advanced product candidate, MYK-461, is an orally-administered small molecule designed to reduce excessive cardiac muscle contractility leading to HCM and is currently being evaluated in three Phase 1 clinical trials. A cornerstone of the MyoKardia platform is the Sarcomeric Human Cardiomyopathy Registry, or SHaRe, a multi-center, international repository of clinical and laboratory data on individuals and families with genetic heart disease, which MyoKardia helped form in 2014. MyoKardia believes that SHaRe, currently consisting of data from approximately 10,000 individuals, is the world's largest registry of patients with heritable cardiomyopathies. MyoKardia's purpose is to improve the lives of patients and families suffering from cardiovascular disease by creating targeted therapies that can change the course of their condition. For more information, please visit

CONTACT: Media Contacts:

         Katie Engleman
         Pure Communications, Inc.

MyoKardia, Inc.